About Allevi
Allevi is a company based in Philadelphia (United States) founded in 2014 by Ricky Solorzano was acquired by 3D Systems in May 2021. It operates as a Direct-to-Consumer (D2C). Allevi has raised $3.58 million across 5 funding rounds from investors including 3D Systems, Penn Medicine and 500 Global. Allevi offers products and services including Allevi 3D Bioprinters and Bioinks. Allevi operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
- Headquarter Philadelphia, United States
- Founders Ricky Solorzano
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allevi, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.58 M (USD)
in 5 rounds
-
Latest Funding Round
$1 M (USD), Seed
Oct 30, 2019
-
Investors
3D Systems
& 5 more
-
Employee Count
Not available
-
Acquired by
3D Systems
(May 06, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Allevi
Allevi offers a comprehensive portfolio of products and services, including Allevi 3D Bioprinters and Bioinks.
Advanced bioprinters are offered for 3D tissue engineering.
Various bioinks are provided for tissue-specific bioprinting applications.
People of Allevi
Unlock access to complete
Software Development Team
86 people
Sales and Marketing
30 people
Leadership Team
29 people
Senior Team
20 people
Product Management Team
17 people
Finance and Accounting
8 people
Legal and Compliance
8 people
Operations Team
7 people
Unlock access to complete
Funding Insights of Allevi
Allevi has successfully raised a total of $3.58M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $1 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allevi
Allevi has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include 3D Systems, Penn Medicine and 500 Global.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and acceleration are provided to tech startups.
|
Locked | Locked | Locked | |
|
Startup accelerator
|
Locked | Locked | Locked | |
|
Technology ecosystem growth is supported in Southeastern Pennsylvania.
|
Locked | Locked | Locked |
Investor details for Allevi
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allevi
Investment portfolio details for Allevi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allevi
Detailed financials for Allevi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allevi Comparisons
Peer comparison for Allevi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allevi
Allevi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Bioprinting technology and tissue therapeutics for regenerative medicine are developed.
|
|
| Locked | Locked | Locked |
Provider of 3D printing of tissue biomaterials for medical research and clinical applications
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
Developer of integrated 3D printing and tissue-engineering platform
|
Detailed competitors of Allevi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allevi
Complete news archive for Allevi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allevi
Allevi was founded in 2014.
Allevi is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Ricky Solorzano is the current CEO of Allevi. They have also founded this company.
Allevi is a funded company, having raised a total of $3.58M across 5 funding rounds to date.
Allevi, part of 3D Systems since 2021, is focused on delivering advanced 3D bioprinting technologies and materials. Solutions are developed for tissue engineering, organ-on-a-chip, and disease modeling. Their bioprinters and bioinks are utilized by researchers globally to address challenges in regenerative medicine, drug discovery, and clinical research. Applications are supported across sectors like cancer biology, vaccine development, and stem cell therapeutics.
Allevi's top competitors include Nuclera Nucleics, Aspect Biosystems and Collplant.
Allevi offers Allevi 3D Bioprinters and Bioinks.
Allevi has 6 investors. Key investors include 3D Systems, Penn Medicine, 500 Global, Dreamit, and Ben Franklin Technology Partners.